Policy & Ethics

GWAS and Polygenic Risk Scores (PGS)

Americans aren't all that eager to get COVID shots—at least that's the impression reporters gave us for months.

Nearly three years ago I wrote how the science behind US opioid policies was deeply fla

Mountaintops have been pushed into neighboring valleys; rivers have been made unswimmable and unfishable to get at the coal seams beneath. The fallout from coal-fired power plants has made other lakes and ponds lifeless.

Earlier this month, the Massachusetts Department of Public Health released Data Brief: Opioid‐​Related Overdose Deaths Among Massachusetts

72 percent of Americans believe that federal public health institutions play a pivotal role in the nation's health care system, though fewer than 40 percent of people trust these agencies to fulfill that obligation.

When we look back on the COVID-19 pandemic, we'll be forced to address a number of vexing questions.

It is impossible to spend a career in drug discovery research without having the following argument dozens of times: Someone: "Drug prices are too high. We should break the patents and let generic companies make them cheaply."

This is what ACSH does and has done for more than four decades. We report on the science. We try to be as accurate and encompassing all the facts that we know at the time of publication.

The introduction of COVID vaccines created a conundrum for public health officials: the clinical trials showed that the shots effectively prevented severe illness and death, but there initially weren't enough doses to go around, and it was unclear